56 Taken together, it is clear that GIPR signalling affects bone turnover, but the overall significance of these effects need to be fully determined
That raises the question: What happens to peoples health after they stop taking these medications
Reported complications described in some GLP-1 drug claims have included: Severe or persistent gastrointestinal symptoms , such as ongoing nausea, vomiting, or abdominal pain Delayed stomach emptying (gastroparesis) , which has been described by some individuals as involving bloating, nausea, vomiting, or difficulty tolerating food Intestinal complications , including reduced bowel activity (ileus), which may involve abdominal discomfort, cramping, or vomiting Gallbladder-related conditions , such as gallstones or gallbladder inflammation Blood-clot-related conditions , including deep vein thrombosis or pulmonary embolism, described in some reports and legal filings Vision-related problems , including reports involving non-arteritic anterior ischemic optic neuropathy (NAION) discussed in connection with semaglutide in certain contexts Not everyone who takes a GLP-1 medication experiences these issues, and the relationship between GLP-1 drugs and reported complications continues to be evaluated in legal proceedings
Clinical findings show noticeable improvements within just 12 weeks, including up to an 83% reduction in appetite and more stable post-meal glucose levels
Prescription drug prices in the U.S
Its an added benefit to any engine, which has high performance
)
